Tiotropium bromide inhalation - Pulmatrix
Alternative Names: HandiHaler; PUR-0200; PUR0217a; PUR0228a; PUR0228b; PUR0228c; PUR0230c; VR 410Latest Information Update: 21 Nov 2021
At a glance
- Originator Pulmatrix
- Developer Pulmatrix; Viatris Inc
- Class Antiasthmatics; Antibronchitics; Epoxy compounds; Esters; Small molecules; Thiophenes; Tropanes
- Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Chronic obstructive pulmonary disease
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in Bulgaria (Inhalation, Powder)
- 13 Jun 2018 Pharmacodynamics and safety data from a phase I trial in Chronic obstructive pulmonary disease released by Pulmatrix
- 07 Jun 2018 Pulmatrix and Vectura plan a phase I/II study in Chronic obstructive pulmonary disease by end-2018